

Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach

Jun Haeng Lee, Jae G. Kim¹, Hye-Kyung Jung², Jung Hoon Kim³, Woo Kyoung Jeong⁴, Tae Joo Jeon⁵, Joon Mee Kim⁶, Young Il Kim⁷, Keun Won Ryu⁸, Seong-Ho Kong⁹, Hyoung-Il Kim¹⁰, Hwoon-Yong Jung¹¹, Yong Sik Kim¹², Dae Young Zang¹³, Jae Yong Cho¹⁴, Joon Oh Park¹⁵, Do Hoon Lim¹⁶, Eun Sun Jung¹⁷, Hyeong Sik Ahn¹⁸, and Hyun Jung Kim¹⁸

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, ¹Department of Medicine, Chung-Ang University College of Medicine, ²Department of Internal Medicine, Ewha Medical Research Institute, Ewha Womans University School of Medicine, ³Department of Radiology and Institute of Radiation Medicine, Seoul National University, College of Medicine, ⁴Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, ⁵Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, ⁶Department of Pathology, Inha University School of Medicine, Incheon, ⁷Department of Surgery, Ewha Womans University School of Medicine, Seoul, ⁸Center for Gastric Cancer, National Cancer Center, Goyang, ⁹Department of Surgery, Seoul National University Hospital, ¹⁰Department of Surgery, Yonsei University College of Medicine, ¹¹Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, ¹²Department of Internal Medicine, Korea University College of Medicine, Seoul, ¹³Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, ¹⁴Department of Medical Oncology, Yonsei University College of Medicine, ¹⁵Department of Medicine, ¹⁶Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, ¹⁷Department of Pathology, The Catholic University of Korea, Seoul St. Mary's Hospital, ¹⁸Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea

Although gastric cancer is quite common in Korea, the treatment outcome is relatively favorable compared to those in western countries. However, there are currently no Korean multidisciplinary guidelines for gastric cancer. Experts from related societies developed guidelines de novo to meet Korean circumstances and requirements, including 23 recommendation statements for diagnosis (n=9) and treatment (n=14) based on relevant key questions. The quality of the evidence was rated according to the GRADE evidence evaluation framework: the evidence levels were based on a systematic review of the literature, and the recommendation grades were classified as either strong or weak. The applicability of the guidelines was considered to meet patients' view and preferences in the context of Korea. The topics of the guidelines cover diagnostic modalities (endoscopy, endoscopic ultrasound, and radiologic diagnosis), treatment modalities (surgery, therapeutic endoscopy, chemotherapy, and radiotherapy), and pathologic evaluation. An external review of the guidelines was conducted during the finalization phase.

Key Words: Stomach neoplasms; Multidisciplinary; Guidelines

Introduction

1. Background, purpose, and scope of the clinical practice guidelines for gastric cancer

Recently, the cancer incidence rate has increased in South Korea. According to data from the National Cancer Information Center, under the Ministry of Health and Welfare, the rate has significantly increased by 3.3% annually during 1999~2008.^{1,2} According to 2008 data, 1 in 3 Koreans might have cancer, with probabilities of 37.2% for men, assuming a mean life expectancy of 77 years, or 30.5% for women, assuming a mean life expectancy of

Correspondence to: Jae G. Kim
Department of Medicine, Chung-Ang University College of Medicine, 84 Heukseok-ro, Dongjak-gu, Seoul 156-861, Korea
Tel: +82-2-6299-3147, Fax: +82-2-825-7571
E-mail: jgkimd@cau.ac.kr
Received June 26, 2014
Accepted June 26, 2014

*This is a secondary publication with minor modifications based on an original guideline written in Korean (Korean J Gastroenterol 2014;63:66-81). The Editor-in-Chief of both Journal agreed on the publication of this article.

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

83 years. The effective treatment has increased the survival rate of gastric cancer patients. However, the prognosis remains relatively poor, with a 5-year survival rate of 63.1% during 2004~2008.¹ According to the data on the cause of mortality, 28.6% of the 246,942 total cancer-related deaths in 2009 were caused by malignant neoplasms, among which gastric cancer was the leading cause of cancer-related deaths.² Economic burden related with gastric cancer is considerably high. In 2007, the Health Insurance Review and Evaluation Service indicated that the total medical costs incurred by gastrointestinal diseases (excluding meals, selective treatment fees, and medication costs from the total expenses paid for Health Insurance Reimbursement) were approximately 3.65 trillion won. The medical costs incurred by malignant gastrointestinal diseases accounted for 36.6% of the above amount, and gastric cancer accounted for 10.9% (390 billion won) of all gastrointestinal diseases, the highest percentage for a single disease (unpublished data).

The present clinical practice guideline is intended for use in both male and female adult patients with gastric cancer. This guideline, which is based on domestic and overseas evidences, have been developed to suit Korea's current medical practices and to ensure their widespread adoption in clinical practice. It was intended to help all medical staffs at the primary, secondary, and tertiary care medical institutions including physicians, surgeons, radiologists, pathologists, family doctors, and general practitioners. Additionally, it was designed to allow patients and populations to find optimum care by providing adequate medical information. Furthermore, it was intended for widespread adoption in order to increase the standard of gastric cancer treatment, thereby contributing to improvement in the patients' quality of life, as well as in the national health care. It will also provide information on clinical practices and principles for medical residents and other medical staffs.

The present guideline is specific and comprehensive for gastric cancer diagnosis and treatment; however, it does not address issues related to prevention, screening, and care of pediatric patients. In addition, it does not address controversial issues with inadequate evidence. However, the nominal group technique was applied to include consensus of the clinically important issues with weak evidences.

2. Composition and progress of guideline development group

The present guideline was prepared as a designated project assignment (no. 1020440) under the Research and Development Program for Cancer Control, conducted by the Ministry of Health and Welfare, South Korea. This guideline was prepared in an integrated and comprehensive manner through an interdisciplinary approach

that included the Korean Academy of Medical Sciences, the Korean Association of Internal Medicine, the Korean Society for Radiation Oncology, the Korean Society of Pathologists, the Korean College of *Helicobacter* and Upper Gastrointestinal Research, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Gastroenterology, the Korean Cancer Association, the Korean Society of Radiology, the Korean Gastric Cancer Association, and the Korean Society of Nuclear Medicine, along with the participation of experts in the guideline development methodology. To develop this guideline, the Organizing Committee for Clinical Practice Guidelines for Gastrointestinal Cancer, the Development Committee for Standard Clinical Practice Guidelines for Gastric Cancer, and the Review Committee for Standard Clinical Practice Guidelines for Gastric Cancer were established, and the members were recommended by each participant associations and societies (<http://www.guideline.or.kr>).

3. Literature search, evaluation, and preparation of recommendations

The fundamental and important issues concerning gastric cancer diagnosis and treatment were selected as key questions according to the patient, intervention, comparator, and outcome (PICO). Search terms for each respective key question were selected according to the medical subject headings (MeSH) terms of National Library of Medicine. For each key question, the inclusion/exclusion criteria were determined and the search words were properly combined to conduct the literature search. PubMed, MEDLINE and the Cochrane Library were used for the international literature search, while KoreaMed was used for the purpose of domestic literature search. The literature search was conducted only for the documents published from 1980~2011 in either English or Korean.

To evaluate the validity of the documents selected as evidence, a systematic and consistent evaluation method was adopted. In order to apply different evaluation methods, the documents were classified according to the study design.³ To evaluate randomized controlled studies, the risk of bias (ROB) method of Cochrane Collaboration was adopted.⁴ The Review Manager (RevMan) 5 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2012) and GRADEpro program (Jan Broeck, Andrew Oxman, Holger Schünemann, 2008) were used to arrange the evidence and evidence summary table.⁵ To evaluate non-randomized controlled studies, the Newcastle-Ottawa evaluation scale was applied. To evaluate diagnostic studies, the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool was used;⁶ accordingly, the evaluations were classified as 'yes', 'no', or 'not clear' for 11 assessable items among the 14 items.

The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method was used for the evidence summary.^{7,8} Levels of evidence of studies were ranked according to the type of research, with a high level evidence for randomized clinical trials and a low level evidence for observational studies. Next, the qualitative level of the corresponding study was increased or decreased after considering the factors that influenced the quality of each study. The levels of evidence were classified as high-quality, A; moderate-quality, B; low-quality, C; and very low-quality, D. For cases with no evidence or difficult to analyze, a fifth classification (no evidence or difficult to analyze, E) was added and used (Table 1).

For the grading of recommendations, (1) a balance of desirable and undesirable effects, (2) evidence quality, and (3) values and preferences were taken into account, according to the GRADE method. Any area with difficult-to-determine recommendations is not mentioned in the present guideline, but will be reviewed during the next guideline development. The grades of recommendations are divided into (1) strong recommendations and (2) weak recommendations (Table 1). A strong recommendation indicates that it is strongly recommended for most patients because compliance with this recommendation for a specific intervention will result in a desirable rather than an undesirable effect, along with a high quality of evidence and a better value and preference, compared to other interventions. A weak recommendation indicates that it is better for many patients to comply with this recommendation because despite rather weak evidence, a desirable effect has been shown. With a weak recommendation, some patients or medical staff might select different interventions according to the values or preferences.

4. Review and approval process

Based on the present guideline as developed by the Development Committee and reviewed by the Review Committee, a public hearing was held on October 29, 2011. The concerned experts,

patients and other interested people participated the hearing. Revisions that reflected the opinions expressed in the public hearing were made. This guideline was then approved by the Korean Association of Internal Medicine, the Korean Cancer Association, the Korean Society of Pathologists, the Korean College of *Helicobacter* and Upper Gastrointestinal Research, the Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Radiology, the Korean Surgical Society, the Korean Gastric Cancer Association, the Korean Society for Radiation Oncology, and the Korean Society of Nuclear Medicine.

5. Renewal procedure and monitoring

The present guideline for gastric cancer will be available free of cost at the web sites of the Korean Academy of Medical Sciences (<http://www.kams.or.kr/>), the Korean Association of Internal Medicine (<http://www.kaim.or.kr/>), the Korean Society for Radiation Oncology (<http://www.kosro.or.kr/>), the Korean Society of Pathologists (<http://www.pathology.or.kr/>), the Korean Society of *Helicobacter* and Upper Gastrointestinal Research (<http://hpylori.or.kr/>), the Korean Society of Gastrointestinal Endoscopy (<http://www.gie.or.kr/>), the Korean Society of Gastroenterology (<http://www.gastrokorea.org/>), the Korean Cancer Association (<http://www.cancer.or.kr/>), the Korean Society of Radiology (<http://www.radiology.or.kr/>), the Korean Gastric Cancer Association (<http://www.kgca-i.or.kr/>), and the Korean Society of Nuclear Medicine (<http://www.ksnm.or.kr/>), as well as through Facebook and Twitter, where monitoring can be processed and all opinions regarding this guideline are welcome. The guidelines will be renewed in 3 to 5 years based on the accumulated clinical evidence.

6. Absence of conflicts of interest

The present guideline was prepared as a designated project assignment, entitled the “Development of clinical practice guidelines methods for gastrointestinal cancer and clinical practice guidelines for gastric cancer/colon cancer” (no. 1020440), under R&D Program for Cancer Control, conducted by the Ministry of Health and Welfare. The members comprised of a principal investigator, Hyeong Sik Ahn (Department of Preventive Medicine, Korea University College of Medicine, Seoul), a principal investigator for gastric cancer guideline, Jae Gyu Kim (Department of Medicine, Chung-Ang University College of Medicine, Seoul), and a principal investigator for colon cancer guideline, Jun Won Uhm (Department of Surgery, Korea University College of Medicine, Seoul). The contents of the present guideline were not influenced by the opinions of financially sponsoring entities. All of the members who partici-

Table 1. Levels of evidence and grades of recommendation

Levels of evidence
A. High-quality evidence
B. Moderate-quality evidence
C. Low-quality evidence
D. Very low-quality evidence
E. No evidence or difficult to analyze
Grades of recommendation
1. Strong recommendation
2. Weak recommendation

pated in the development of the present guideline have submitted a confirmatory document with their signatures to assure that there were no conflicts of interest. None of the participants were involved in issues related to conflicts of interest.

7. Limitations of the present guideline

One of the major limitations of the present guideline is that there is not enough evidences in Korea. Data from studies in other countries may be slightly different in terms of epidemiological and clinical aspects. Considering the established therapeutic efficacy of current treatment methods, it is difficult to conduct new randomized controlled studies in some areas because of the ethical issues.

Endoscopic diagnosis

1. Conventional endoscopy

1) Upper gastrointestinal endoscopy and biopsy

Upper gastrointestinal endoscopy is the primary tool for the diagnosis of gastric cancer. By using the proper technique such as air infusion and removal of mucus, it is possible to observe the entire stomach clearly. One of the major advantages of endoscopy is that tissue sampling can be performed immediately by using biopsy forceps. The recently introduced magnifying endoscopy may help to observe the gastric lesion.

To achieve the best results, endoscopy should be performed by properly trained endoscopists using appropriate endoscopic devices. Biopsy is necessary because there are limitations to the sensitivity and specificity of direct observation for diagnosing gastric cancer.⁹ Normally, acquisition of more than 4 tissue samples is recommended in order to increase the diagnostic accuracy. However, a fewer number of samples might be enough in patients considering endoscopic resection. Biopsy has a low sensitivity for detecting Borrmann type IV advanced gastric cancers. Endoscopic clips or dye injection can be used to determine the resection margin during the surgery.¹⁰ If it is difficult to localize the cancer lesion, as in rare cases, an intraoperative endoscopy can be performed.¹¹

Recommendation: Upper gastrointestinal endoscopy is the primary diagnostic tool for gastric cancer (Recommendation Grade 1, Evidence Level E).

Recommendation: During upper gastrointestinal endoscopy, biopsies of suspicious or possible gastric cancer lesions should be performed (Recommendation Grade 1, Evidence Level E).

2) Chromoendoscopy

Chromoendoscopy is easy and simple method that allows better visualization of the lesions with unclear color changes or minute surface irregularities. It is also useful in determining the lateral borders during endoscopic submucosal dissection (ESD). Dyes include methylene blue, indigocarmine, acetic acid, and crystal violet, and among them, indigo carmine is the most commonly used.¹² After indigocarmine spraying, the dye fills the depressed mucosal sites, thus highlighting the surface irregularities. Such characteristics can help to estimate the depth of invasion of early gastric cancers (EGCs) and to determine the range of resection for endoscopic therapies.

Recommendation: Chromoendoscopy is useful in the determination of the lateral margin during endoscopic resection of early gastric cancer (Recommendation Grade 2, Evidence Level E).

2. Endoscopic ultrasonography

Endoscopic ultrasonography (EUS) can be used to evaluate the depth of invasion of gastric cancers and the presence of local lymph node metastases. Because of the widespread use of laparoscopic surgery for EGC, evaluation of the stage of gastric cancer before therapy has become more important. A recent meta-analysis¹³ of 54 studies, including 5,601 gastric cancer patients, showed that EUS had a relatively good sensitivity and specificity for differentiating between T1 to 2 and T3 to 4 lesions (0.86 and 0.91, respectively). However, the sensitivity and specificity for detecting lymph node metastases were lower (0.69 and 0.84, respectively).¹³ According to a recent Korean study,¹⁴ which compared the accuracies of white light endoscopy and EUS, the accuracy of white light endoscopy for predicting the depth of invasion of EGCs was 73.7%, while that of EUS was only 67.4%. Therefore, the usefulness of endoscopic ultrasonography before endoscopic therapy for gastric cancer remains controversial.

Recommendation: In some patients, endoscopic ultrasonography (EUS) is useful in addition to white light endoscopy and CT before endoscopic or surgical resection of gastric cancer (Recommendation Grade 2, Evidence Level D).

Radiology

1. Upper gastrointestinal series

The upper gastrointestinal series is a radiologic test that is widely used for the diagnosis of gastric cancer as it is safe and non-invasive without the need for specific preparation. It is useful as a

preoperative test because of its high sensitivity and the ability to visualize the lesion location accurately and objectively.^{15,16} To perform an upper gastrointestinal series, it is important to obtain appropriate mucosal coating and gastrointestinal distention. For this purpose, a 240% weight per volume (w/v) high-density barium solution is generally used in gastrointestinal series. To ensure the accuracy of the upper gastrointestinal series, a single-contrast study including the compression and mucosal relief views should be combined with a double-contrast study that uses a high concentration of barium to coat the mucosa via air distention.¹⁷

Recommendation: Upper gastrointestinal series is useful for the diagnosis of gastric cancer (Recommendation Grade 1, Evidence Level C).

2. Computed tomography

From the late 1970s, computed tomography (CT) is a diagnostic and preoperative test for detecting gastrointestinal tumors including gastric cancer. To date, special CT techniques for evaluating the stomach have been widely used to detect and diagnose gastric cancers, to determine the optimal treatment method via accurate staging, and to identify therapeutic effects after surgery or anti-cancer treatments. After the multidetector row CT (MDCT) was introduced, the diagnostic accuracy has increased and the detection of small lesions, including EGCs, has improved.

1) Multidetector row computed tomography

After the introduction of MDCT, the z-axis resolution improved, and thus the ambiguity of lesions due to partial volume averaging, which was considered as the disadvantage of conventional-type single-channel helical CT, was decreased.

When using MDCT to diagnose gastric cancer, according to related literatures, at least a 4-channel MDCT is required, with a detector collimation ≤ 2.5 mm, an imaging section thickness ≤ 5 mm, and the administration of approximately 500 ml of water or an effervescent agent; the patient is then instructed to change position until each part of the stomach is properly distended.¹⁸⁻²⁰ Additionally, it is better to perform dynamic CT after contrast enhancement because arterial-phase imaging allows easy detection of enhanced mucosal lesions of the stomach, while portal venous-phase imaging provides more accurate information including the depth of invasion of gastric cancer and the involvement of adjacent organs and facilitates the evaluation of lymph node metastases. In addition, delayed-phase imaging might also be useful because in some cases there is

enhanced fibrosis surrounding the gastric cancer, thus allowing a more accurate evaluation of tumor infiltration into the gastric wall. The reconstruction of arterial-phase and portal venous-phase images will permit CT angiography, which provides preoperative evaluation of perigastric blood vessels.

Upon examining the reports of preoperative tumor node metastasis (TNM) staging via MDCT, the accuracies ranged from 67.9% to 90.9% for T (median value, 82.1%) and from 56.9% to 86% for N (median value, 69.5%). In particular, the specificity for T4, which determines whether surgery is indicated, ranged from 81.8% to 99.4% (median value, 96.5%).^{18,20-24} Nevertheless, CT allows clinicians to diagnose advanced gastric cancer that has spread to the peritoneum or shows distant metastases, thereby preventing unnecessary surgeries.

CT is also useful for evaluating the therapeutic effects after anticancer therapy. The Response Evaluation Criteria in Solid Tumors (RECIST), which is used to evaluate response to treatment in solid cancers, states that CT is among the most useful modalities, along with magnetic resonance (MR) for evaluating the sizes of solid tumors.²⁵

Recommendation: CT should be performed for the preoperative staging of gastric cancer (Recommendation Grade 1, Evidence Level D).

2) Three-dimensional computed tomography gastrography; virtual gastroscopy

This technique utilizes the 3-dimensional reconstruction of CT images to provide similar imaging to the upper gastrointestinal series or endoscopy. Its advantages include 3-dimensional representation of the anatomical location of gastric cancers, facilitation of surgical planning, and the ability to detect depressed areas or changes in gastric mucosal folds that are difficult to observe in cross-sectional CT images; thus helping in identifying small lesions on the gastric mucosal surface in EGC.¹⁹

3. Magnetic resonance imaging

Magnetic resonance imaging facilitates the diagnosis of extra-serosal invasion or invasion into adjacent organs and the identification of distant metastasis, and it is therefore useful in preoperative staging of gastric cancer. In particular, it has been widely used for the evaluation of liver metastases. Recently, liver-specific MR contrast agents have been developed and this allows us to achieve more accurate diagnoses of hepatic metastases in the future.²⁶

Recommendation: In some patients, liver magnetic resonance imaging (MRI) with contrast enhancement is useful for the diagnosis of liver metastasis of gastric cancer (Recommendation Grade 2, Evidence Level E).

Nuclear imaging

1. Role of [¹⁸F]-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of gastric cancer

Although [¹⁸F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is increasingly being adopted for the diagnosis of cancer and determination of therapeutic effects and staging, its role in detection of primary lesions is limited in some cases. According to the existing literature, the PET detection rate of EGC is less than 50%, and therefore PET alone is not recommended for gastric cancer screening in asymptomatic patients.²⁷ In a study on the diagnosis of advanced gastric cancer, the success rate of PET in establishing the diagnosis ranged from 62% to 98% because FDG uptake varies according to the characteristics of gastric cancer.²⁸⁻³¹ For example, PET/CT shows strong FDG uptake in the intestinal type gastric cancer and demonstrates high sensitivity, while a relatively low sensitivity was reported in diffuse-type tumors with a low level of FDG uptake.³² Considering the above findings, endoscopy and barium upper gastrointestinal series are still considered to be more effective for diagnosing EGC.

2. Staging and prediction of prognosis

FDG PET/CT has a limited role in the detection of early primary gastric cancers. However, this is the same as that with contrast-enhanced CT, because it is difficult to evaluate primary tumors accurately due to the characteristics of the stomach. Additionally, according to the pathologic evaluation of biopsies, the cell densities and the degree of malignancies are not uniform;^{32,33} and therefore although PET/CT allows evaluation of the degree of metabolic activity and targets the highly malignant areas, its role is still limited with regard to accurate measurement of the depth of invasion into the gastric wall.

Next, when evaluating invasion into adjacent lymph nodes, the ability of PET to evaluate glucose metabolism is expected to allow more accurate detection of metastases to the local lymph nodes. According to Mochiki et al.,³¹ the diagnostic performance of PET for N1 lymph nodes is not satisfactory, but this might have little

clinical significance because these lymph nodes will be resected during gastric cancer surgery. On the other hand, invasion of lymph nodes in the N3 group is classified as distant metastasis, and it is very important to determine distant metastasis accurately. Yun et al.³⁴ reported that PET might provide useful information on distant lymph node invasion.

In a study by Hillner et al.³⁵ of 3,025 gastric cancer patients, distant metastases to other internal organs was evaluated, and patient management was altered significantly after the PET results in 37% of cases and PET showed better results than the conventional tests in the detection of liver metastases.³⁶ In terms of skeletal evaluation, bone scanning still plays an important role and PET scanning can play a compensatory role in the detection of osteolytic bone metastasis.²⁹

In PET scanning, the degree of FDG uptake in primary gastric cancer is expected to be an additional predictive factor along with the conventional anatomical imaging-adapted TNM staging.^{32,33} Additionally, peritoneal metastasis is also one of the important prognostic factors of gastric cancer and PET has a higher specificity (99%), lower sensitivity (35%), and equal accuracy when compared to CT for detection of peritoneal metastasis.³⁷

Recommendation: In some patients, fluorodeoxyglucose/positron emission tomography/computerized tomography (FDG PET/CT) is useful for gastric cancer staging (Recommendation Grade 2, Evidence Level D).

3. Evaluation of recurrence

Postoperative evaluation of recurrence is very important in the management of gastric cancer. Sites of gastric cancer recurrence include adjacent organs, lymphatic system, blood circulation, and peritoneum. Consequently, recurrence sites include the local area, liver, lungs, skeletal system, peritoneum, and many other sites. Changes in the anatomical structure after gastric surgery can make it difficult to diagnose recurrence accurately in many cases. Some studies have reported that PET is better than conventional CT in terms of specificity and positive predictive value.^{33,38} Several studies reported that PET scanning after gastric distension due to water intake is useful for determining postoperative recurrence.³⁹ According to the recent studies that assessed PET/CT, PET generally provides better results for the evaluation of gastric cancer recurrence compared to contrast-enhanced CT⁴⁰ and this might be due to the combination of anatomic and functional data.

Recommendation: In some patients, FDG PET/CT is useful for the evaluation of recurrence after surgery (Recommendation Grade 2, Evidence Level D).

4. Determination of therapeutic effects

During gastric cancer therapy, each individual patient presents with a different gastric cancer cell type, degree of differentiation, malignant potential of tumors, and depth of invasion, and therefore, a careful approach is essential in selecting anticancer drugs. Ott et al.³⁹ performed baseline PET scans and additional PET scans after 2 to 3 cycles of chemotherapy, and they proposed that the therapeutic effects of anticancer drugs can be determined by comparison of these two scans.³⁹ Recently, many reports have suggested that the efficacy of therapeutic options can be determined by evaluating not only changes in size, but also changes in lesion metabolism. Therefore, the role of FDG PET/CT in management of gastric cancer will continue to expand in the future.

Surgery

1. Principles of gastric cancer surgery

1) Gastric resection

The standard surgical procedures for gastric cancer are distal subtotal gastrectomy (gastric resection of two-thirds) for cancers in the lower or middle third of the stomach and total gastrectomy for cancers in the upper or middle third of the stomach, as well as radical lymphadenectomies. Limited or function-preserving surgeries include pylorus-preserving gastrectomy, local resection, segmental resection, and proximal gastrectomy. Before performing limited surgeries, factors such as the location of the lesion, the extent of lymphadenectomy, and resection margins should be considered. Proximal gastrectomy is mainly performed for EGCs in the upper stomach, but care should be taken to prevent the risk of developing reflux esophagitis.⁴¹⁻⁴⁴

Recommendation: Surgery is the standard treatment for gastric cancer. Curative gastric surgery is composed of complete resection of the primary lesion with safe margin, radical lymphadenectomy, and gastrointestinal reconstruction (Recommendation Grade 1, Evidence Level E).

Recommendation: Proximal gastrectomy may replace total gastrectomy for limited indications (Recommendation Grade 2, Evidence Level D).

2) Lymphadenectomy

Perigastric lymphadenectomy can be performed in patients with EGC. Here, lymph node dissections are performed for group 1 lymph nodes plus LN7, 8, 9, [+11p].^{45,46} Peri- and extragastric lymphadenectomy is performed in patients with advanced gastric cancer (AGC) and patients with EGC who have suspected lymph node metastasis. Lymphadenectomy beyond perigastric lymph nodes is not currently accepted as a standard therapy, but it is considered to be an extensive operation. The effects of para-aortic lymph node dissection have not been reported.⁴⁷

Recommendation: In early gastric cancer, the extent of radical lymphadenectomy may be reduced. (Recommendation Grade 2, Evidence Level D).

3) Combined resection

Combined resection of involved organs can be performed in cases showing direct invasion into the adjacent organs,⁴⁸⁻⁵⁸ gastric cancers in the greater curvature with muscularis propria invasion, suspected splenic hilar lymph node involvement,⁵⁹⁻⁶² suspected distant metastasis,⁶³⁻⁶⁶ and in patients undergoing palliative surgery.

4) Reconstruction

Only a few studies have compared the differences between postoperative reconstruction methods. A few studies have compared Billroth-I and Billroth-II and have reported that the 2 types of anastomosis did not show significant differences with regard to therapeutic performance or difficulty in ingestion.^{67,68} Additionally, Roux-en-Y gastric bypass might be superior to Billroth-I anastomosis in terms of postoperative bilious reflux.⁶⁹

Recommendation: Gastrojejunostomy, loop gastrojejunostomy and Roux-en-Y anastomosis are acceptable reconstruction methods after distal gastrectomy (Recommendation Grade 2, Evidence Level D).

2. Surgery for early gastric cancers

1) Surgical indications in early gastric cancer

EGC refers to gastric cancers limited to the mucosal and submucosal layers regardless of lymph node metastasis; the frequency of lymph node metastasis is approximately 5% in mucosal cancers and approximately 20% in submucosal cancers.^{70,71} Any EGC without distant metastasis can be a candidate for surgery which is composed with gastric resection and lymph node dissection.^{72,73}

2) Open surgery vs. laparoscopic surgery

In most of the retrospective studies of EGC, laparoscopic surgery was not inferior to open surgery.⁷⁴⁻⁸⁴ However, the number of prospective studies of laparoscopic surgery is insufficient.^{85,86}

Recommendation: Laparoscopic surgery is acceptable for early gastric cancer. (Recommendation Grade 2, Evidence Level C).

3. Surgery for advanced gastric cancer

1) Surgical indications in advanced gastric cancer

AGC is defined as gastric cancers with invasion into the proper muscle and/or deeper layers. In cases with perigastric organ invasion, combined radical resection can be performed. In cases with distant metastasis, resection limited to the primary tumor can be performed to prevent or treat cancer-related symptoms such as bleeding and obstruction, and to improve the quality of life.⁸⁷⁻⁸⁹ In unresectable cases, palliative surgeries such as gastrojejunal bypass can be performed.⁹⁰

Endoscopic therapy

1. Absolute indications

Traditionally, the standard treatment for gastric cancer has been surgery. Endoscopic mucosal resection, which was first introduced in Japan in 1984, and the more recently introduced ESD can replace standard surgery if applied to limited stages of EGCs. Endoscopic therapy can minimize surgical complications, and the quality of life is only slightly affected. In multiple retrospective studies, survival after endoscopic treatment is comparable to that after surgery.⁹¹⁻⁹⁶ However, according to a Cochrane review, there are no randomized controlled trials comparing endoscopic therapy and surgery.⁹⁷

Theoretically, the indication for endoscopic therapy is EGC without risk of lymph node metastasis. However, it is impossible to diagnose lymph node metastases accurately before treatment. Therefore, indications for endoscopic treatment were defined based on the analysis of surgical date of lymph node metastasis.⁹⁸⁻¹⁰² Currently, the absolute indications of endoscopic therapy for EGC include (1) lesions limited to the mucosal layer, (2) well and/or moderately differentiated adenocarcinomas, (3) tumors ≤ 2 cm in length, (4) absence of ulcer or ulcer-scar tissue, and (5) tumors without lymphovascular involvement.¹⁰⁰ Because it is impossible to clearly determine the depth of invasion or lymphovascular involvement, additional treatment is sometimes required based on the pathological results.

Recommendation: Endoscopic therapy can be performed in early gastric cancer within absolute indications (Recommendation Grade 1, Evidence Level D).

2. Expanded indications

With the development of ESD techniques, there have been attempts to extend the indications of endoscopic resection.^{96,103,104} Expanded indications include (1) well or moderately differentiated adenocarcinoma in the mucosal layer without an ulcer regardless of the size, (2) well or moderately differentiated adenocarcinoma measuring less than 3 cm in the mucosal layer with ulcer, (3) small (less than 2 cm) intramucosal cancer with undifferentiated histology, and (4) well or moderately differentiated adenocarcinoma with minute submucosal invasion (≤ 500 μm , SM1).

3. Follow-up

The National Comprehensive Cancer Network guidelines recommend that follow-up after gastric cancer treatment should be conducted every 3 to 6 months for the first three years after R0 resection. For 3 to 5 years, the follow-up interval is 6 months, and there it is yearly. The guideline states that complete blood count, biochemical tests, radiologic studies, and endoscopy can be performed if they are clinically necessary.¹⁰⁵ The recurrence rate after endoscopic therapy for EGC is 3.3% to 14.0%. It is recommended that patients should undergo an endoscopic follow-up at least annually because of the risk of missing multiple synchronous cancers.

Recommendation: Endoscopic follow-up is recommended at least annually after endoscopic therapy for early gastric cancer (Recommendation Grade 1, Evidence Level E).

Chemotherapy

1. Postoperative adjuvant chemotherapy for gastric cancer

Gastric cancer recurs in 22% to 45% of patients after curative resection.^{106,107} In this regard, there have been many studies that evaluated the effect of adjuvant chemotherapy. In meta-analyses of clinical trials between 1980 and 2000, adjuvant chemotherapy increased the rate of survival.^{108,109} In 2010, the Global Advanced/Adjuvant Stomach Tumor Research International Collaboration (GASTRIC) group performed a meta-analysis of 17 clinical trials, which showed that adjuvant chemotherapy increased the survival duration and that fluoropyrimidine-containing therapy lowered the

risk of death.¹¹⁰

In a western study, administration of epirubicin+cisplatin+5-fluorouracil (5-FU): ECF chemotherapy after surgery significantly increased the overall survival (hazard ratio [HR], 0.75) and disease-free survival (HR, 0.66).¹¹¹ It is difficult to accept this regimen as a standard treatment in Korea because only 42.5% of the patients underwent D2 lymph node dissection. In this context, clinical studies in Korea and Japan have attempted to determine the effect of adjuvant chemotherapy after D2 lymph node dissection. Among the 1,059 patients with stage II disease, a comparison was made between an S-1 (tegafur+gimeracil+oteracil)-treated group and an untreated group after D2 dissection.¹¹² The S-1-treated group had a significantly higher 5-year survival rate, compared to the surgery-alone group (71.7% vs. 61.1%; HR, 0.669).¹¹³ A clinical trial (CLASSIC trial) conducted by Korean researchers among 1,035 patients with stage II, IIIa, and IIIb (T3N2) diseases showed that the group treated with capecitabine and oxaliplatin combination therapy had a significantly higher 3-year survival rate compared to the untreated group (74% vs. 60%).¹¹⁴

In conclusion, S-1 monotherapy and capecitabine+oxaliplatin therapy can be standard adjuvant treatments for stage II and III diseases after D2 lymph node dissection. In the future, well-designed clinical trials are needed for the development of more effective postoperative adjuvant therapies.

Recommendation: Adjuvant chemotherapy with either S-1 monotherapy or capecitabine+oxaliplatin combination therapy can be used after surgery for gastric cancer (Recommendation Grade 1, Evidence Level B).

2. First-line palliative chemotherapy for recurrent and/or metastatic gastric cancer

The main goals of chemotherapy for recurrent and metastatic gastric cancers are to prolong the survival and to improve the quality of life by providing symptom palliation. Since 1990s, 4 small randomized Phase III clinical trials that were published¹¹⁵ have consistently shown survival benefit (approximately 3 to 7 months) and improved quality of life in the patients receiving palliative chemotherapy, compared to the patients receiving best supportive care alone.¹¹⁶⁻¹¹⁸

Recommendation: First-line palliative chemotherapy is recommended for recurrent and/or metastatic gastric cancer patients in the context of performance status, medical comorbidity and toxicity profile (Recommendation Grade 1, Evidence Level B).

Among the gastrointestinal cancers, gastric cancer is known to respond relatively well to chemotherapy. Chemotherapeutic agents for gastric cancer including 5-FU, mitomycin C, cisplatin, and etoposide have shown response rates of at least 10% when administered as monotherapies. Other newer agents including irinotecan, oral etoposide, paclitaxel, docetaxel, and pegylated doxorubicin have shown response rates ranging from 10% to 20%. Generally, the response rates are low with very short response duration (within 3~4 months) when anticancer drugs are administered alone. Therefore, combination chemotherapies have been attempted in order to increase the response rates and prolong the survival time; in studies in which combination chemotherapy was administered, response rates of 25% to 50% and median survival of 6 to 12 months have been reported.¹¹⁹⁻¹²²

A recent meta-analysis of randomized trials showed that combination chemotherapy significantly improves the survival, compared to single chemotherapy or best supportive care alone.¹¹⁵ First-line palliative chemotherapy with a two-drug combination of fluoropyrimidines and platinum is preferred for patients with advanced or metastatic disease. Three-drug combination chemotherapy with docetaxel or epirubicin should be reserved for medically fit patients with a good performance status.

Recently, molecular targeted agents such as trastuzumab, bevacizumab, cetuximab, and lapatinib have been tested with the standard chemotherapy for recurrent and metastatic gastric cancers. Based on the results of the ToGA study, which showed a significant improvement in the median overall survival (13.5 vs. 11.1 months) with the addition of trastuzumab to chemotherapy (5-FU or capecitabine and cisplatin), trastuzumab in combination with chemotherapy is recommended for patients having HER2 overexpression or amplification (HER2 IHC 3+ or HER2 IHC 2+ with FISH/SISH+).¹²³ However, the addition of either bevacizumab,¹²⁴ cetuximab,¹²⁵ or lapatinib¹²⁶ to chemotherapy failed to show survival benefit in recent phase III clinical trials.

Recommendation: First-line palliative chemotherapy regimens include fluoropyrimidines (5-FU, capecitabine, S-1), platinum (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), irinotecan and anthracyclines (doxorubicin, epirubicin). Single or combination (two or three drugs) therapy can be given (Recommendation Grade 1-2, Evidence Level B-C).

Preferred regimens for first-line chemotherapy include DCF (docetaxel, cisplatin, and 5-FU) and its modification (1B), ECF and its modification (1B), fluoropyrimidines (5-

FU, capecitabine, or S-1)+cisplatin (1B), fluoropyrimidines (5-FU or capecitabine)+oxaliplatin (2B), fluoropyrimidines (5-FU)+irinotecan (2C), taxanes (docetaxel or paclitaxel)+cisplatin (2C), and trastuzumab with fluoropyrimidines (5-FU or capecitabine)+cisplatin for HER2-overexpressing adenocarcinomas (1B). Single agent chemotherapy using fluoropyrimidines (5-FU, capecitabine, or S-1; 2C) can be given for patients who are medically unfit for receiving combination chemotherapy.

3. Second-line palliative chemotherapy for recurrent and/or metastatic gastric cancer

A complete cure cannot be expected in recurrent/metastatic gastric cancer patients. Instead, an extended survival period and alleviation of symptoms can be expected with chemotherapy. However, there are no established results for second-line palliative chemotherapy, although progressive diseases have been detected in many patients who received first-line palliative chemotherapy.

Recently, 2 randomized phase III clinical trials reported significantly extended survival durations after second-line palliative chemotherapy compared to best supportive care in advanced patients who had received first-line palliative chemotherapy for metastatic gastric cancer.^{127,128} Among these patients (Eastern Cooperative Oncology Group performance statuses: mostly 0 to 2), the group that received irinotecan or docetaxel as a second-line palliative chemotherapy agent showed a significant increase in the overall survival duration compared to the group that received best supportive care. A meta-analysis of the results from these 2 studies showed that second-line chemotherapy had a significant effect on survival duration when compared to best supportive care (HR, 0.52; 95% confidence interval, 0.30~0.90).

Recommendation: In cases of recurrent and/or metastatic gastric cancer after first-line palliative chemotherapy, second-line palliative chemotherapy is recommended if the patient's performance status is good (Recommendation Grade 1, Evidence Level B).

Although a standard second-line palliative chemotherapy has not been established for advanced cancer, the type, dosage, and administration method of second-line chemotherapy should be determined after consideration of the toxicity of the intended agent, differences between patients, the first-line chemotherapy type, performance status, accompanying diseases, available agents, and economic aspects. For second-line palliative chemotherapy, regimens based on existing phase II clinical trial results can be adopted or regimens from well-designed clinical trials can be used. The recommended second-line palliative chemotherapies, based

on clinical trial results, include paclitaxel-based chemotherapies (paclitaxel; paclitaxel with doxorubicin, capecitabine, or 5-FU and leucovorin; and paclitaxel with cisplatin or carboplatin), docetaxel-based chemotherapies (docetaxel; docetaxel with cisplatin or oxaliplatin; docetaxel with 5-FU or capecitabine; docetaxel with etoposide; docetaxel with epirubicin; and DCF if not used as a first-line therapy), irinotecan-based chemotherapies (irinotecan; irinotecan with cisplatin; irinotecan with 5-FU and leucovorin or capecitabine; and irinotecan with mitomycin), platinum-based chemotherapies (5-FU or capecitabine with cisplatin; 5-FU or capecitabine with cisplatin and trastuzumab for Her2-neu overexpressing adenocarcinomas if not used as a first-line therapy; fluoropyrimidine [capecitabine or 5-FU and leucovorin] with oxaliplatin; pegylated liposomal doxorubicin with oxaliplatin; and epirubicin, cisplatin and 5-FU [ECF] or epirubicin, cisplatin and capecitabine [ECX] if not used as a first line therapy), fluoropyrimidine-based chemotherapies (fluoropyrimidine [S-1, capecitabine, or 5-FU] and leucovorin); fluoropyrimidine [S-1 or 5-FU and leucovorin] with mitomycin; 5-FU with methotrexate; and capecitabine with doxorubicin).

Radiation therapy

1. Neoadjuvant radiation therapy

Neoadjuvant radiation therapy can be performed before surgery to increase the possibility of performing radical resection in patients with locally advanced gastric cancer. To date, there have been three randomized controlled trials regarding neoadjuvant radiation therapy. Zhang et al.¹²⁹ reported a significant increase in the 5- and 10-year overall survival and resection rates in neoadjuvant radiation therapy group compared to surgery alone group, when 370 patients with gastric adenocarcinomas located in the gastric cardia were compared. Skoropad et al.^{130,131} reported that neoadjuvant radiation therapy tended to increase survival rates among patients with preoperatively positive lymph node metastases or clinical T3 or higher stage.

Recommendation: Neoadjuvant radiation therapy may be considered in patients with locally advanced gastric cancer (Recommendation Grade 2, Evidence Level C).

2. Adjuvant radiation therapy

Adjuvant radiation therapy can be performed alone or in combination with chemotherapy if there is a possibility of recurrence after curative resection. Postoperative recurrences are mainly

divided into local recurrences, regional recurrences, and distant metastases. Among these, local and regional recurrences can be reduced with adjuvant radiation therapy and eventually the cure rate can be increased. There have been several studies which have compared surgery alone with surgery plus postoperative adjuvant chemoradiotherapy in gastric cancer patients who underwent curative resection.

According to the result of a randomized controlled trial in 556 patients, conducted by Macdonald et al.,¹³² the adjuvant chemoradiotherapy group showed increased survival duration compared to surgery alone group. However, lymph node dissection was either not performed at all or was only partially performed in 90% of the patients, and this limitation made it difficult to apply the findings of this study to the patients in Korea, where D2 lymph node dissection is considered a standard treatment. Therefore, this study showed that adjuvant chemoradiotherapy would increase the survival period for gastric cancer patients without extended lymph node dissection.

An observation study of 990 patients who underwent D2 lymph node dissection, conducted by Kim et al.,¹³³ showed that adjuvant chemoradiotherapy resulted in a reduced recurrence rate and a better survival rate compared to that in surgery alone group. Therefore, adjuvant chemoradiotherapy can be considered as a postoperative adjuvant therapy for gastric cancer patients, including those who have undergone D2 lymph node dissection. Meanwhile, according to the results of an observational study conducted by Dikken et al.,¹³⁴ adjuvant chemoradiotherapy reduced the local recurrence rate after D1 lymph node dissection, but no difference was observed after D2 lymph node dissection. Hence, a randomized phase 3 clinical study is needed to determine the effects of adjuvant chemoradiotherapy after extended lymph node dissection.

Recommendation: Chemoradiotherapy may be considered as a postoperative adjuvant therapy for radically resected gastric cancer patients (Recommendation Grade 2, Evidence Level C).

Although it is not possible to obtain a curative effect, palliative radiation therapy can be used to alleviate patients' symptoms and to increase the quality of life of patients. Palliative radiation therapy can be applied to reduce severe bleeding or difficulty in swallowing caused by stomach cancers and severe pain due to metastasis to other organs (e.g., brain, bone, and abdomen).

Pathologic evaluation

1. Handling of gastric cancer specimens

Gastric cancer specimens are obtained by endoscopic biopsy,

endoscopic resection including polypectomy, and surgical resection. In case of endoscopic biopsy, the biopsy sites and number of specimens should be clearly defined. For the pathologic evaluation of endoscopic mucosal resection (EMR) or ESD specimens, the samples should be spread on a plate without overstretching, fixed with a pin to prevent contraction, and placed in formalin. Mapping can be performed when the specimen is submitted properly. The guideline items of pathologic diagnosis are described only when mapping is performed. If mapping is not possible, only the histological classification and differentiation can be mentioned in the pathologic report. Surgically resected specimens should be opened along the greater or lesser curvature of stomach without causing damage to the lesion. The specimen should be stretched and pinned onto a plate to prevent contraction. The stomach should be immediately fixed in 10% neutral formalin for routine microscopic examination. The amount of fixative should be sufficient to completely submerge the specimens. At least 3 to 4 hours are required to fix biopsies and at least 8 hours are required to fix the resection samples. Fixed specimens should be cut into sections according to the recommendations of the Gastrointestinal Pathology Study Group of Korean Society of Pathologists.¹³⁵ For frozen section or tissue banking, the use of a fresh unfixed tissue is recommended.

2. Pathologic diagnosis of gastric cancer

The World Health Organization classification¹³⁶ is used for histological classification of gastric cancers, and Lauren classification¹³⁷ can be added in it. If histological classification is difficult, immunohistochemical or histochemical staining will be helpful. Tubular adenocarcinomas should be classified according to the grade of differentiation, for which the 2-, 3-, or 4-tier grading system can be used. Generally, the 3-tier grading system is used.

Grade 1: Well differentiated; >95% gland forming

Grade 2: Moderately differentiated; 50%~95% gland forming

Grade 3: Poorly differentiated; 0%~49% gland forming

The following items should be included in the pathologic report, along with optional information according to the recommendations of the Gastrointestinal Pathology Study Group of Korean Society of Pathologists.¹³⁸ For the following items in the pathological report, all processes should be performed properly including prescribing, tissue processing, and diagnosis. Additional reasonable prescriptions and tests should be added for providing more information. The pathologic staging for gastric cancer is based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition.¹³⁹

Biopsy: Histological classification, differentiation

Endoscopic resection*: Histological classification, differentiation, tumor size, depth of invasion, presence of lymphatic vascular invasion, resection margin status

Surgery: Histological classification, differentiation, tumor size, depth of invasion, proximal and distal resection margins, number of resected regional lymph nodes, number of lymph nodes with tumor invasion

*The items can be described only when the pathologic interpretation is possible after mapping.

3. Pathologic evaluation of lymph node metastasis

Accurate pathologic evaluation of lymph nodes is mandatory for cancer staging. As many lymph nodes as possible should be microscopically examined in the radically resected specimens. The pN staging is determined using the conventional hematoxylin and eosin stain. Tumor staging is based on the AJCC staging system.¹³⁹

4. Pathologic markers associated with targeted agents for gastric cancer

Some changes in the protein or gene expression in gastric cancers are recognized as important prognostic and therapeutic markers. Immunohistochemical staining is one of the useful methods for detecting the change in protein expression. For targeted therapy, Her2 protein expression tests or gene amplification tests are necessary for selecting gastric or gastroesophageal cancer patients. When the score of immunohistochemical staining for Her2 is 3+, targeted therapy is indicated. In case the score of immunohistochemical staining for Her2 is 2+, an additional FISH (or SISH) test is recommended. However, even when the score of immunohistochemical staining for Her2 is 0 or 1+, Her2 gene amplification is present in 2% to 11% of patients by FISH (or SISH). Therefore, the FISH (or SISH) test is not meaningless even when the immunohistochemical staining score is 0 or 1+.¹⁴⁰⁻¹⁴⁴

Recommendation: Her2 protein expression or gene amplification tests are useful in the management of gastric or gastroesophageal cancer patients (Recommendation Grade 1, Evidence Level B).

References

1. Cancer statistics [Internet]. Goyang: National Cancer information Center [cited 2014 Feb 5]. Available from: http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.
2. Cause of death statistics [Internet]. Daejeon: Korean Statistical Information Service [cited 2014 Feb 5]. Available from: <http://kosis.kr/index/index.jsp>.
3. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovich C, Song F, et al; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. *Health Technol Assess* 2003;7:iii-x, 1-173.
4. Turk DJ, Kozarek RA, Botoman VA, Patterson DJ, Ball TJ. Disposable endoscopic biopsy forceps: comparison with standard forceps of sample size and adequacy of specimen. *J Clin Gastroenterol* 1991;13:76-78.
5. Dandalides SM, Carey WD, Petras R, Achkar E. Endoscopic small bowel mucosal biopsy: a controlled trial evaluating forceps size and biopsy location in the diagnosis of normal and abnormal mucosal architecture. *Gastrointest Endosc* 1989;35:197-200.
6. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003;3:25.
7. Yang R, Vuitch F, Wright K, McCarthy J. Adequacy of disposable biopsy forceps for gastrointestinal endoscopy: a direct comparison with reusable forceps. *Gastrointest Endosc* 1990;36:379-381.
8. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, et al; GRADE Working Group. Incorporating considerations of resources use into grading recommendations. *BMJ* 2008;336:1170-1173.
9. Kobayashi S, Kasugai T, Yamazaki H. Endoscopic differentiation of early gastric cancer from benign peptic ulcer. *Gastrointest Endosc* 1979;25:55-57.
10. Ryu KW, Lee JH, Choi JJ, Bae JM. Preoperative endoscopic clipping: localizing technique of early gastric cancer. *J Surg Oncol* 2003;82:75-77.
11. Park DJ, Lee HJ, Kim SG, Jung HC, Song IS, Lee KU, et al. Intraoperative gastroscopy for gastric surgery. *Surg Endosc* 2005;19:1358-1361.
12. Shim CS. Staining in gastrointestinal endoscopy: clinical applications and limitations. *Endoscopy* 1999;31:487-496.
13. Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric cancer: a meta-analysis. *Gastrointest Endosc* 2011;73:1122-

1. Cancer statistics [Internet]. Goyang: National Cancer information Center [cited 2014 Feb 5]. Available from: http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.

- 1134.
14. Choi J, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Comparison of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. *Endoscopy* 2010;42:705-713.
 15. Low VH, Levine MS, Rubesin SE, Laufer I, Herlinger H. Diagnosis of gastric carcinoma: sensitivity of double-contrast barium studies. *AJR Am J Roentgenol* 1994;162:329-334.
 16. Murakami R, Tsukuma H, Ubukata T, Nakanishi K, Fujimoto I, Kawashima T, et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. *Cancer* 1990;65:1255-1260.
 17. Gelfand DW. The multiphasic upper gastrointestinal examination. *Radiol Clin North Am* 1994;32:1067-1081.
 18. Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. *Radiology* 2007;242:472-482.
 19. Kim JH, Eun HW, Hong SS, Auh YH. Early gastric cancer: virtual gastroscopy. *Abdom Imaging* 2006;31:507-513.
 20. Kim HJ, Kim AY, Oh ST, Kim JS, Kim KW, Kim PN, et al. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. *Radiology* 2005;236:879-885.
 21. Kumano S, Murakami T, Kim T, Hori M, Iannaccone R, Nakata S, et al. T staging of gastric cancer: role of multi-detector row CT. *Radiology* 2005;237:961-966.
 22. Makino T, Fujiwara Y, Takiguchi S, Tsuboyama T, Kim T, Nushijima Y, et al. Preoperative T staging of gastric cancer by multi-detector row computed tomography. *Surgery* 2011;149:672-679.
 23. Park SR, Kim MJ, Ryu KW, Lee JH, Lee JS, Nam BH, et al. Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. *Ann Surg* 2010;251:428-435.
 24. Yan C, Zhu ZG, Yan M, Zhang H, Pan ZL, Chen J, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. *J Surg Oncol* 2009;100:205-214.
 25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228-247.
 26. Goshima S, Kanematsu M, Watanabe H, Kondo H, Shiratori Y, Onozuka M, et al. Hepatic hemangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI. *AJR Am J Roentgenol* 2010;195:941-946.
 27. Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. *Br J Cancer* 2007;97:1493-1498.
 28. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. *Radiol Clin North Am* 2001;39:883-917.
 29. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. *J Nucl Med* 2003;44:690-699.
 30. Buyyounouski MK, Klump WJ, Konski A, Wu H, Adler LP. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. *Clin Nucl Med* 2005;30:118-119.
 31. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. *World J Surg* 2004;28:247-253.
 32. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. *Eur J Nucl Med Mol Imaging* 2003;30:288-295.
 33. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. *Eur J Nucl Med Mol Imaging* 2002;29:525-529.
 34. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. *J Nucl Med* 2005;46:1582-1588.
 35. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. *J Nucl Med* 2008;49:1928-1935.
 36. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. *Radiology* 2002;224:748-756.
 37. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. *J Nucl*

- Med 2003;44:1407-1412.
38. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. *Clin Radiol* 2003;58:215-221.
 39. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. *J Clin Oncol* 2003;21:4604-4610.
 40. Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, et al. The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making? *Eur J Nucl Med Mol Imaging* 2011;38:64-73.
 41. Harrison LE, Karpeh MS, Brennan MF. Total gastrectomy is not necessary for proximal gastric cancer. *Surgery* 1998;123:127-130.
 42. An JY, Youn HG, Choi MG, Noh JH, Sohn TS, Kim S. The difficult choice between total and proximal gastrectomy in proximal early gastric cancer. *Am J Surg* 2008;196:587-591.
 43. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Hutawatari N, et al. Clinical significance of total gastrectomy for proximal gastric cancer. *Anticancer Res* 2008;28:2875-2883.
 44. Yoo CH, Sohn BH, Han WK, Pae WK. Proximal gastrectomy reconstructed by jejunal pouch interposition for upper third gastric cancer: prospective randomized study. *World J Surg* 2005;29:1592-1599.
 45. The Korean Gastric Cancer Association, ed. Gastric cancer and gastrointestinal disease. Seoul: Ilchokak, 2011.
 46. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer* 2011;14:113-123.
 47. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008;359:453-462.
 48. Nunobe S, Hiki N, Ohyama S, Fukunaga T, Seto Y, Yamaguchi T. Survival benefits of pancreatoduodenectomy for gastric cancer: relationship to the number of lymph node metastases. *Langenbecks Arch Surg* 2008;393:157-162.
 49. Shchepotin IB, Chorny VA, Nauta RJ, Shabahang M, Buras RR, Evans SR. Extended surgical resection in T4 gastric cancer. *Am J Surg* 1998;175:123-126.
 50. Maehara Y, Oiwa H, Tomisaki S, Sakaguchi Y, Watanabe A, Anai H, et al. Prognosis and surgical treatment of gastric cancer invading the pancreas. *Oncology* 2000;59:1-6.
 51. Mita K, Ito H, Fukumoto M, Murabayashi R, Koizumi K, Hayashi T, et al. Surgical outcomes and survival after extended multiorgan resection for T4 gastric cancer. *Am J Surg* 2012;203:107-111.
 52. Ozer I, Bostanci EB, Orug T, Ozogul YB, Ulas M, Ercan M, et al. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. *Am J Surg* 2009;198:25-30.
 53. Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma invading adjacent organs. *J Surg Oncol* 2009;100:115-120.
 54. Carboni F, Lepiane P, Santoro R, Lorusso R, Mancini P, Sperduti I, et al. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. *J Surg Oncol* 2005;90:95-100.
 55. Oñate-Ocaña LF, Becker M, Carrillo JF, Aiello-Crocifoglio V, Gallardo-Rincón D, Brom-Valladares R, et al. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. *J Surg Oncol* 2008;98:336-342.
 56. Kobayashi A, Nakagohri T, Konishi M, Inoue K, Takahashi S, Itou M, et al. Aggressive surgical treatment for T4 gastric cancer. *J Gastrointest Surg* 2004;8:464-470.
 57. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Surgical outcomes in patients with T4 gastric carcinoma. *J Am Coll Surg* 2006;202:223-230.
 58. Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. *Ann Surg* 2002;236:159-165.
 59. Shin SH, Jung H, Choi SH, An JY, Choi MG, Noh JH, et al. Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. *Ann Surg Oncol* 2009;16:1304-1309.
 60. Sano T, Yamamoto S, Sasako M; Japan Clinical Oncology Group Study LCOG 0110-MF. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. *Jpn J Clin Oncol* 2002;32:363-364.
 61. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg* 2006;93:559-563.
 62. Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, Nagano Y, et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. *J Gastrointest Surg* 2007;11:1039-1044.
 63. Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Sur-

- vival benefit of metastasectomy for Krukenberg tumors from gastric cancer. *Gynecol Oncol* 2004;94:477-482.
64. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al. Hepatic resection for metastatic tumors from gastric cancer. *Ann Surg* 2002;235:86-91.
 65. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. *Ann Oncol* 2008;19:1146-1153.
 66. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. *J Clin Oncol* 2003;21:799-806.
 67. Chareton B, Landen S, Manganas D, Meunier B, Launois B. Prospective randomized trial comparing Billroth I and Billroth II procedures for carcinoma of the gastric antrum. *J Am Coll Surg* 1996;183:190-194.
 68. Kang KC, Cho GS, Han SU, Kim W, Kim HH, Kim MC, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Comparison of Billroth I and Billroth II reconstructions after laparoscopy-assisted distal gastrectomy: a retrospective analysis of large-scale multicenter results from Korea. *Surg Endosc* 2011;25:1953-1961.
 69. Kojima K, Yamada H, Inokuchi M, Kawano T, Sugihara K. A comparison of Roux-en-Y and Billroth-I reconstruction after laparoscopy-assisted distal gastrectomy. *Ann Surg* 2008;247:962-967.
 70. Kim JB, Hur YS, Yang HK. Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. *Ann Surg Oncol* 1995;2:308-313.
 71. An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Kim S. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. *Ann Surg* 2007;246:749-753.
 72. Lai JF, Kim S, Kim K, Li C, Oh SJ, Hyung WJ, et al. Prediction of recurrence of early gastric cancer after curative resection. *Ann Surg Oncol* 2009;16:1896-1902.
 73. Youn HG, An JY, Choi MG, Noh JH, Sohn TS, Kim S. Recurrence after curative resection of early gastric cancer. *Ann Surg Oncol* 2010;17:448-454.
 74. Kim MC, Kim W, Kim HH, Ryu SW, Ryu SY, Song KY, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Risk factors associated with complication following laparoscopy-assisted gastrectomy for gastric cancer: a large-scale Korean multicenter study. *Ann Surg Oncol* 2008;15:2692-2700.
 75. Song J, Lee HJ, Cho GS, Han SU, Kim MC, Ryu SW, et al; Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. *Ann Surg Oncol* 2010;17:1777-1786.
 76. Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N; Japanese Laparoscopic Surgery Study Group. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. *Ann Surg* 2007;245:68-72.
 77. Huscher CG, Mingoli A, Sgarzini G, Brachini G, Binda B, Di Paola M, et al. Totally laparoscopic total and subtotal gastrectomy with extended lymph node dissection for early and advanced gastric cancer: early and long-term results of a 100-patient series. *Am J Surg* 2007;194:839-844; discussion 844.
 78. Fujiwara M, Kodera Y, Misawa K, Kinoshita M, Kinoshita T, Miura S, et al. Longterm outcomes of early-stage gastric carcinoma patients treated with laparoscopy-assisted surgery. *J Am Coll Surg* 2008;206:138-143.
 79. Hwang SH, Park do J, Jee YS, Kim MC, Kim HH, Lee HJ, et al. Actual 3-year survival after laparoscopy-assisted gastrectomy for gastric cancer. *Arch Surg* 2009;144:559-564; discussion 565.
 80. Lee SW, Nomura E, Bouras G, Tokuhara T, Tsunemi S, Tanigawa N. Long-term oncologic outcomes from laparoscopic gastrectomy for gastric cancer: a single-center experience of 601 consecutive resections. *J Am Coll Surg* 2010;211:33-40.
 81. Pugliese R, Maggioni D, Sansonna F, Costanzi A, Ferrari GC, Di Lernia S, et al. Subtotal gastrectomy with D2 dissection by minimally invasive surgery for distal adenocarcinoma of the stomach: results and 5-year survival. *Surg Endosc* 2010;24:2594-2602.
 82. Jiang X, Hiki N, Nunobe S, Fukunaga T, Kumagai K, Nohara K, et al. Long-term outcome and survival with laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. *Surg Endosc* 2011;25:1182-1186.
 83. Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Kim JG, et al. Long-term outcomes and survival after laparoscopy-assisted distal gastrectomy for gastric cancer: three-year survival analysis of a single-center experience in Korea. *J Surg Oncol* 2011;104:511-515.
 84. Pak KH, Hyung WJ, Son T, Obama K, Woo Y, Kim HI, et al.

- Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute. *Surg Endosc* 2012;26:130-136.
85. Hur H, Jeon HM, Kim W. Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy for T2b advanced gastric cancers: three years' experience. *J Surg Oncol* 2008;98:515-519.
 86. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). *Ann Surg* 2010;251:417-420.
 87. Sano T. Evaluation of the gastric cancer treatment guidelines of the Japanese Gastric Cancer Association. *Gan To Kagaku Ryoho* 2010;37:582-586.
 88. Sasaki T. Discussion for gastric cancer treatment guidelines in Japan. *Nihon Rinsho* 2003;61:13-18.
 89. Kahlke V, Bestmann B, Schmid A, Doniec JM, Kuchler T, Kremer B. Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life. *World J Surg* 2004;28:369-375.
 90. Sarela AI, Yelluri S; Leeds Upper Gastrointestinal Cancer Multidisciplinary Team. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? *Arch Surg* 2007;142:143-149; discussion 149.
 91. Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, et al. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001;48:225-229.
 92. Manner H, Rabenstein T, May A, Pech O, Gossner L, Werk D, et al. Long-term results of endoscopic resection in early gastric cancer: the Western experience. *Am J Gastroenterol* 2009;104:566-573.
 93. Choi KS, Jung HY, Choi KD, Lee GH, Song HJ, Kim do H, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. *Gastrointest Endosc* 2011;73:942-948.
 94. Jang JS, Choi SR, Qureshi W, Kim MC, Kim SJ, Jeung JS, et al. Long-term outcomes of endoscopic submucosal dissection in gastric neoplastic lesions at a single institution in South Korea. *Scand J Gastroenterol* 2009;44:1315-1322.
 95. Uedo N, Iishi H, Tatsuta M, Ishihara R, Higashino K, Takeuchi Y, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. *Gastric Cancer* 2006;9:88-92.
 96. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. *Br J Surg* 2010;97:868-871.
 97. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. *Cochrane Database Syst Rev* 2009;(4):CD004276.
 98. Chung JW, Jung HY, Choi KD, Song HJ, Lee GH, Jang SJ, et al. Extended indication of endoscopic resection for mucosal early gastric cancer: analysis of a single center experience. *J Gastroenterol Hepatol* 2011;26:884-887.
 99. Kang HJ, Kim DH, Jeon TY, Lee SH, Shin N, Chae SH, et al. Lymph node metastasis from intestinal-type early gastric cancer: experience in a single institution and reassessment of the extended criteria for endoscopic submucosal dissection. *Gastrointest Endosc* 2010;72:508-515.
 100. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. *J Clin Oncol* 2005;23:4490-4498.
 101. Song SY, Park S, Kim S, Son HJ, Rhee JC. Characteristics of intramucosal gastric carcinoma with lymph node metastatic disease. *Histopathology* 2004;44:437-444.
 102. Hyung WJ, Cheong JH, Kim J, Chen J, Choi SH, Noh SH. Application of minimally invasive treatment for early gastric cancer. *J Surg Oncol* 2004;85:181-185; discussion 186.
 103. Lee H, Yun WK, Min BH, Lee JH, Rhee PL, Kim KM, et al. A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. *Surg Endosc* 2011;25:1985-1993.
 104. Ahn JY, Jung HY, Choi KD, Choi JY, Kim MY, Lee JH, et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. *Gastrointest Endosc* 2011;74:485-493.
 105. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, et al; NCCN Gastric Cancer Panel. Gastric cancer. *J Natl Compr Canc Netw* 2010;8:378-409.
 106. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al; Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. *Br J Surg* 2003;90:1113-1119.
 107. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. *Br J Surg* 2000;87:236-242.
 108. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: re-

- visiting a meta-analysis of randomised trials. *Eur J Cancer* 1999;35:1059-1064.
109. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). *Ann Oncol* 2000;11:837-843.
 110. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. *JAMA* 2010;303:1729-1737.
 111. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20.
 112. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007;357:1810-1820.
 113. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. *J Clin Oncol* 2011;29:4387-4393.
 114. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012;379:315-321.
 115. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol* 2006;24:2903-2909.
 116. Glimelius B, Ekström K, Hoffman K, Graf W, Sjöden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. *Ann Oncol* 1997;8:163-168.
 117. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. *Cancer* 1993;72:37-41.
 118. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. *Br J Cancer* 1995;71:587-591.
 119. Cocconi G, DeLisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. *Cancer Treat Rep* 1982;66:1263-1266.
 120. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. *JAMA* 1985;253:2061-2067.
 121. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). *J Clin Oncol* 1984;2:1372-1381.
 122. The Gastrointestinal Tumor study Group. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma: The Gastrointestinal Tumor study Group. *Cancer* 1982;49:1362-1366.
 123. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.
 124. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* 2011;29:3968-3976.
 125. Lordick F, Kang YK, Salman P, Oh SC, Bodoky G, Kurteva GP, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. *ASCO Meeting Abstracts* 2013;31 Suppl:4021.
 126. Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. *ASCO Meeting Abstracts* 2013;31

- Suppl:LBA4001.
127. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Eur J Cancer* 2011;47:2306-2314.
128. Park SH, Lim DH, Park K, Lee S, Oh SY, Kwon H, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). *ASCO Annual Meeting Proceedings* 2011;29 Suppl:abstr 4004.
129. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. *Int J Radiat Oncol Biol Phys* 1998;42:929-934.
130. Skoropad VY, Berdov BA, Mardynski YS, Titova LN. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. *Eur J Surg Oncol* 2000;26:773-779.
131. Skoropad V, Berdov B, Zagrebina V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. *J Surg Oncol* 2002;80:72-78.
132. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.
133. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. *Int J Radiat Oncol Biol Phys* 2005;63:1279-1285.
134. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. *J Clin Oncol* 2010;28:2430-2436.
135. The Study Group for Gastrointestinal Pathology, Korean Society of Pathologists. Guidelines for Pathologic Study of Gastric Cancer. *Korean J Pathol* 1992;26:154-163.
136. International Agency for Research on Cancer, ed. WHO classification of tumors of the digestive system. 4th ed. Lyon: World Health Organization, 2010.
137. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965;64:31-49.
138. Kim WH, Park CK, Kim YB, Kim YW, Kim HG, Bae HI, et al. A standardized pathology report for gastric cancer. *Korean J Pathol* 2005;39:106-113.
139. Edge SB; American Joint Committee on Cancer, eds. *AJCC Cancer Staging Manual*. 7th ed. New York (NY): Springer, 2010.
140. Kim A, Bae JM, Kim SW, Gu MJ, Bae YK. HER2 status in gastric adenocarcinomas assessed by immunohistochemistry, automated silver-enhanced in situ hybridization and fluorescence in situ hybridization. *Korean J Pathol* 2010;44:493-501.
141. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. *Hum Pathol* 2007;38:1386-1393.
142. Bilous M, Osamura RY, Rüschoff J, van de Vijver M, Hanna W, Penault-Llorca F, et al. HER-2 amplification is highly homogeneous in gastric cancer. *Hum Pathol* 2010;41:304-305; author reply 305-306.
143. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology* 2008;52:797-805.
144. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. *Oncol Rep* 2006;15:65-71.